Zuoli Pharmaceutical announced on December 14 that on December 12, the company signed a “Multi-micronutrient Injection Asset Group Acquisition Agreement” with Tibet Future Biomedical Co., Ltd. and its two wholly-owned subsidiaries Xuchang Future Pharmaceutical Co., Ltd. and Hefei Future Pharmaceutical Development Co., Ltd. to acquire its multi-micronutrient injection asset group at a total price of 356 million yuan. The contents of the asset group include development/production technical data, marketing licenses, trademarks, patents, contractual rights and obligations, employee labor relationships, etc. for the marketed varieties of “multi-micronutrient injections”, “multi-micronutrient injections” and “multi-micronutrient injections” under development.

Zuoli Pharmaceutical announced on December 14 that on December 12, the company signed a “Multi-micronutrient Injection Asset Group Acquisition Agreement” with Tibet Future Biomedical Co., Ltd. and its two wholly-owned subsidiaries Xuchang Future Pharmaceutical Co., Ltd. and Hefei Future Pharmaceutical Development Co., Ltd. to acquire its multi-micronutrient injection asset group at a total price of 356 million yuan. The contents of the asset group include development/production technical data, marketing licenses, trademarks, patents, contractual rights and obligations, employee labor relationships, etc. for the marketed varieties of “multi-micronutrient injections”, “multi-micronutrient injections” and “multi-micronutrient injections” under development.